Precision BioSciences (NASDAQ:DTIL) Director Geno Germano Buys 2,609 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno Germano bought 2,609 shares of the stock in a transaction on Friday, September 25th. The stock was purchased at an average cost of $6.28 per share, for a total transaction of $16,384.52. Following the acquisition, the director directly owned 47,492 shares of the company’s stock, valued at $298,249.76. The trade was a 5.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Precision BioSciences Trading Up 0.3%

Shares of DTIL stock opened at $6.24 on Tuesday. The stock has a market cap of $172.22 million, a P/E ratio of -2.23 and a beta of 1.24. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. Precision BioSciences, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $9.62. The business has a fifty day simple moving average of $7.37 and a 200-day simple moving average of $7.19.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. On average, analysts forecast that Precision BioSciences, Inc. will post -3.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Precision BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Octagon Capital Advisors LP lifted its stake in shares of Precision BioSciences by 16.6% during the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after buying an additional 318,737 shares during the period. Empery Asset Management LP purchased a new stake in Precision BioSciences in the 4th quarter worth approximately $9,130,000. Affinity Asset Advisors LLC purchased a new stake in Precision BioSciences in the 1st quarter worth approximately $3,289,000. Squarepoint Ops LLC raised its holdings in Precision BioSciences by 212.7% in the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after acquiring an additional 93,258 shares during the last quarter. Finally, Corient Private Wealth LP raised its holdings in Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after acquiring an additional 101,206 shares during the last quarter. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on DTIL. HC Wainwright reiterated a “buy” rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Wall Street Zen lowered Precision BioSciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday, August 5th. Finally, Oppenheimer began coverage on Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

Precision BioSciences Company Profile